Exagen Inc. - Common Stock (XGN)

Management outlined new product launches and an AI acquisition aimed at deeper clinic integration.

Exagen (NASDAQ:XGN) reported third-quarter revenue of $18.4 million, up 7% from a year earlier, as higher test volume and pricing helped the autoimmune diagnostics company post what management described as its strongest third quarter on record. The company reiterated its 2026 revenue forecast of $7

Record revenue and near break-even adjusted EBITDA signal progress toward profitability.

Exagen (NASDAQ:XGN) reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even. Revenue for the quarter ended June 30 rose 16% year over year and 15% sequ

Exagen (XGN) Q1 2026 Earnings Transcript

Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter. The autoimmune diagnostics

Exagen's Q3 2025 results show a revenue beat but a wider-than-expected loss, causing a pre-market stock decline.

Exagen Inc (XGN) beats Q2 2025 revenue estimates with $17.2M but posts wider loss. Stock jumps 6.77% pre-market as investors focus on growth potential.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.